Full-Time

Associate Director

Oncology

Updated on 9/4/2026

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$154.4k - $242.6k/yr

+ Short-term incentives + Long-term incentives + 401(k) match

Massachusetts, USA

Remote

Bachelor's

Category
Biology & Biotech (1)
Required Skills
SharePoint
Data Analysis

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • A minimum of eight years of related experience, such as Regulatory Project Management, is required.
  • Significant experience in global drug development regulations, regulatory submissions, lifecycle management, compliance, business systems technology, and process is required.
  • Experience with at least two major electronic Common Technical Document registrations and several minor amendment filings in the United States or other jurisdictions is required.
  • An understanding of scientific principles and regulatory standards and requirements relevant to global drug development and post-market support is required.
  • Proven ability to provide regulatory operational support and guidance is required.
  • Ability to address critical issues, provide regulatory operational advice, and make reasoned decisions on regulatory operational issues is required.
  • Ability to demonstrate leadership, problem-solving, flexibility, and teamwork is required.
  • Good judgment in elevating and communicating actual or potential issues to line management is required.
  • Active participation in industry groups and forums is expected.
  • Excellent verbal and written communication skills and ability to prepare effective presentations with focused messaging are required.
  • Excellent interpersonal and negotiation skills are required.
  • Ability to collaboratively lead without line authority and work effectively with other departments and external organizations is required.
  • Demonstrated experience leading decision-making within a cross-functional, cross-cultural, global team structure in a matrix environment is required.
  • Excellent organizational skills, ability to multitask, attention to detail, and ability to manage multiple projects within assigned timelines are required.
  • Ability to apply scientific principles to assess issues, collect relevant information, analyze data, establish facts, and draw valid conclusions is required.
  • Analytical and problem-solving skills, including the ability to identify issues and opportunities and direct teams to explore alternatives, are required.
  • Expertise with project management software and tools such as Microsoft Project, OnePager, Office Timeline, and SharePoint is required.
Responsibilities
  • Partner with the Global Regulatory Lead on Global Regulatory Teams to establish and maintain global regulatory project plans and direct execution of team goals.
  • Lead cross-functional submission working groups to deliver successful submissions and filings and outcomes with health authorities for early- to late-phase programs.
  • Provide project management leadership, oversight, direction, and planning for regulatory submissions.
  • Directly support the program Global Regulatory Lead by ensuring effective regulatory project management and operational support for assigned assets.
  • Perform regulatory operational activities and directly oversee vendors providing operational support for assigned programs.
  • Co-lead and facilitate product-specific Global Regulatory Team meetings and cross-functional submission working group meetings.
  • Partner with the Global Regulatory Lead to operationalize and execute the Global Regulatory Strategy Plan and align operational plans with Global Project Management teams and Therapeutic Area and Business Unit asset strategies.
  • Drive Global Regulatory Team and submission working group project teams, maintain focus on deliverables, identify solutions to problems, and develop and maintain integrated regulatory project plans.
  • Provide and oversee regulatory operational support, including drafting forms and cover letters, supporting health authority meetings, coordinating briefing book roundtables, drafting regulatory notifications, managing regulatory document workflows, entering information into regulatory information management systems, and preparing, checking, and tracking regulatory data and lists.
  • Ensure outsourced regulatory operational deliverables from third parties and vendors meet program timelines and company standards.
  • Prepare and deliver reports and metrics on regulatory milestone status, critical issues, constraints, bottlenecks, regulatory risks, and mitigation plans.
  • Collaborate with the Global Regulatory Lead to present operational strategies and plan statuses to key stakeholders through scheduled and ad hoc updates.
  • Drive decision-making processes and escalate issues as needed to support delivery of regulatory milestones.
  • Elevate high-impact business-critical issues and proposed action plans to the Global Regulatory Lead and management in a timely manner.
  • Recommend, plan, and implement process changes through proactive engagement with cross-functional team members and regulatory project management colleagues.
  • Identify and propose solutions for systemic bottlenecks and constraints.
  • Conduct lessons-learned sessions, track project variances, identify root causes, and develop plans to address systemic concerns and issues.
  • Contribute to Takeda's regulatory project management knowledge base and project management processes.
  • Provide training and support to other Regulatory Project Managers as required.
Desired Qualifications
  • A science emphasis in a bachelor's degree is preferred.
  • An advanced degree is preferred.
  • Four years of experience in Global Regulatory Affairs is preferred.
  • Experience working on late-stage filings is highly preferred.
  • Advanced education or credentialing in regulatory affairs and project management is preferred.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
  • ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
  • Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.

What critics are saying

  • The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
  • Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
  • If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.

What makes Takeda unique

  • Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
  • Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
  • Takeda paired discovery teams with Boltz in 2026, embedding AI across research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.